Mellsop Graham, Tapsell Rees, Holmes Pragya
Research Contractor, Auckland, New Zealand.
University of Auckland Waikato Clinical School, Hamilton, New Zealand.
Gen Psychiatr. 2019 Sep 5;32(5):e100088. doi: 10.1136/gpsych-2019-100088. eCollection 2019.
Recently, publications have hypothesised that the demonstrated increase in the incidence of schizophrenia in New Zealand is a side effect of the increased strength of available cannabis derivatives over the last 25+ years and the much more recent increase in the population's use of methamphetamine.
To compare the rates of later schizophrenia between age-matched mental health service users with initial diagnoses as alcohol abusers or illicit drug users.
From the PRIMHD comprehensive national database, all users of the mental health services over a 5-year period who received an ICD-10 presenting diagnosis of alcohol or substance use/abuse were identified. For each person identified, the database was examined for the following 3 years to determine the numbers later diagnosed with schizophrenia.
For the initial alcohol problem people in their twenties, 1.7% were diagnosed as suffering from schizophrenia in the subsequent 3 years. For the initial drug problem people, the rate was 10.9%. Within that drug-using population, the indigenous Maori developed schizophrenia at a higher rate than did the remainder of the population.
These findings in New Zealand require further research into their generalisability, context and explanation.
最近，有出版物提出假设，认为新西兰精神分裂症发病率的上升是过去25年多来可用大麻衍生物效力增强以及近期人口中甲基苯丙胺使用增加的副作用。
比较年龄匹配的最初诊断为酒精滥用者或非法药物使用者的心理健康服务使用者中精神分裂症的发病几率。
从PRIMHD全国综合数据库中，识别出在5年期间接受国际疾病分类第10版（ICD - 10）酒精或物质使用/滥用诊断的所有心理健康服务使用者。对于每个被识别出的人，在接下来的3年里检查数据库，以确定后来被诊断为精神分裂症的人数。
对于二十多岁最初有酒精问题的人，在随后3年里，1.7%被诊断患有精神分裂症。对于最初有药物问题的人，这一比例为10.9%。在该吸毒人群中，本土毛利人患精神分裂症的比例高于其他人群。
新西兰的这些发现需要进一步研究其普遍性、背景及解释。
